Stockpolly
Search
Delisting risk
ADTX · NASDAQ · Biotechnology

Aditxt (ADTX)

Develops immune, diagnostic, infectious disease, women's health, and oncology programs.

$0.0069
At close−0.00 (−12.66%)
Watchlist

In millions of USD, except per-share figures

In millionsQ2 FY23Jun 2023Q3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026
Revenue000000000000
Cost of revenue000000000000
Gross profit000000000000
4881264666354
Research & development014820111111
473344545243
Selling & marketing000000000000
General & administrative473344545243
Other expenses000000000000
Operating income−4−8−8−12−6−5−6−6−6−3−5−4
−1−2−3−3−2−200−1−21−1−12
Interest income000000000000
Interest expense123322001000
Other non-operating income00000000021012
Income before tax−6−10−11−15−8−7−6−6−7−24−5−16
Net income from continuing operations−6−10−11−15−8−7−6−6−7−24−5−16
Net income−6−10−11−15−8−7−5−6−7−24−5−16
EPS, basic$0.00$0.00$0.00$0.00$0.00$0.00−$100.70−$8.12−$3.45−$548.78−$148.00−$790.49
EPS, diluted$0.00$0.00$0.00$0.00$0.00$0.00−$100.70−$8.12−$3.45−$548.78−$148.00−$790.49
Weighted average shares, basic0000000——000
Weighted average shares, diluted0000000——000
EBITDA−4−8−8−12−6−5−5−6−6−24−5−16
Depreciation & amortization000000000000
EBIT−4−8−8−12−6−5−5−6−6−24−5−16